Loma Linda Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Loma Linda University Medical Center has established a new cancer center under the direction of Mark Reeves, MD, PhD, professor of surgery at Loma Linda University and chief of the Section of Surgical Oncology at the Loma Linda Veteran's Administration.

LOMA LINDA, California-Loma Linda University Medical Center has established a new cancer center under the direction of Mark Reeves, MD, PhD, professor of surgery at Loma Linda University and chief of the Section of Surgical Oncology at the Loma Linda Veteran’s Administration.

 The 11,000-square-foot phase 1 stage of the new center was opened on February 15 (see photograph). The center will occupy an anticipated 75,000 square feet when all four planned stages of improvements are completed. LLUMC has already recruited eight new specialists in surgical, orthopedic, gynecologic, thoracic, and medical oncology to lead key initiatives within the new cancer center.

“A key provision of our multi-phase expansion was to bring all of our cancer services together under one roof,” said Judy Chatigny, RN, MSN, executive director of the cancer center. With the phase 1 opening, she said, all medical oncology services can be accessed in one location.

The LLU Cancer Center includes a proton treatment program, surgical robotics program, breast MRI, infusion center, patient navigators, biospecimen tissue lab, and the resources of an academic medical center with its own school of medicine. The cancer center’s 11 “centers of excellence” include breast, thoracic, genitourinary, pediatrics, blood and marrow, gynecologic, neurologic, skin/melanoma, gastrointestinal, head and neck, and soft tissue/skeletal.

LLUMC, a Seventh-Day Adventist institution founded in 1905, is among the largest private medical education centers in the United States and the only one in inland Southern California.

Confetti marks the grand opening celebration of Loma Linda University Medical Center’s Comprehensive Cancer Center.
From left to right, Ruthita Fike, CEO/administrator, LLUMC; Jan Wong, MD, chief of surgical oncology, LLUMC; Jerry Slater, MD, chair, Department of Medicine, LLUMC; C.S. Chen, MD, chief of medical oncology, LLUMC; Roger Hadley, MD, executive vice president of medical affairs, LLU Adventist Health Sciences Center; Judy Chatigny, RN, MSN, executive director, LLU Cancer Center; Larry Sowers, PhD, associate dean of basic sciences, LLU School of Medicine; and Mark Reeves, MD, PhD, medical director, LLU Cancer Center.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content